| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Erucic acid (ERU) (0-100 μM) decreases AsPC-1 cell viability in a concentration-dependent manner and produces H2S [1]. Erucic acid reduces the G0/G1 phase and increases the G2/M and S phases in the AsPC-1 cell cycle, inhibiting cell migration [1]. Erucin (30 μM, 72 h) slows cell migration and causes apoptosis in AsPC-1 cells [1]. In AsPC-1 cells, erucic acid lowers the amounts of phosphorylated ERK1/2 [1]. With an IC50 of 97.7 μM, erucin (0-200 μM, 24 hours) has anti-proliferative action in A549 cells [2]. In A549 cells, erucin (0-50 μM, 24 hours) enhances p53 and p21 protein expression and causes PARP-1 breakage at 50 μM [2]. Erucin decreases the amount of NO, prostaglandin E2 (PGE2), TNF-α, IL-6, and IL-1β that are produced in RAW 264.7 cells in response to LPS [3]. In RAW 264.7 cells, erucin decreases the production of cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) caused by LPS [3]. Erucin prevents RAW 264.7 cells' NFκB signaling from being activated by LPS [3].
|
|---|---|
| ln Vivo |
TPA-induced edema formation is markedly inhibited by erucin (ERU) (0-300 nM) [3]. Neuroprotective effects of erucic acid (30 μmol/kg; intraperitoneal injection; twice weekly for 4 weeks) have been reported [4].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: AsPC-1 Tested Concentrations: 10, 30 and 100 μM Incubation Duration: 72 hrs (hours) Experimental Results: demonstrated a significant and concentration-dependent decrease in cell viability. Cell cycle analysis [1] Cell Types: AsPC-1 Tested Concentrations: 30 μM Incubation Duration: 72 hrs (hours) Experimental Results: The number of cells in G2/M phase increased Dramatically (the number of cells in G2 phase was 36.6% ± 3.5 compared with vehicle-treated cells) / M phase: 24.0% ± 1.3) and S phase (18.1% ± 1.5 compared to vehicle-treated S phase cells: 11.0% ± 0.7), followed by a significant reduction in G0/G1 phase cells (35.1% ± 5.0 vs. vehicle Comparison of treated G0/G1 phase cells: 59.5% ± 1.8. Apoptosis analysis [1] Cell Types: AsPC-1 Tested Concentrations: 30 μM Incubation Duration: 72 hrs (hours) Experimental Results: The total cell number Dramatically increased apoptotic cells (apoptosis Dead and apoptotic live cells; Vehicle: 17.7% ± 2.5 vs. Erucin: 28.7% ± 4.2). Cell proliferation assay[2] Cell Types: A549 Tested Concentrations: 0-200 µM Incubation Duration: 72 h Experimental Results: demonstrated a significant and concentration‐dependent reduction of cell viability. |
| Animal Protocol |
Animal/Disease Models: Female ICR mice (4 weeks old), TPA (12-O-tetradecanoylphorbol-13-acetate)-induced mouse ear edema model [3]
Doses: 0, 100 and 300 nM Route of Administration: Topically applied to mice 30 minutes before topical application of TPA, ear contact Experimental Results: Dramatically inhibited the formation of edema caused by TPA. Animal/Disease Models: Male C57Bl/6 mice (9 weeks old, body weight 25-30 g) [4] Doses: 30 μmol/kg Route of Administration: intraperitonealadministration, twice a week for 4 weeks (via striatum Injection 6-induced brain damage) OHDA) Experimental Results: Induced partial recovery in the rotational behavioral test. TH expression is upregulated. Counteracts neuronal death and DNA fragmentation in 6-OHDA-damaged mice. Increased total GSH and Nrf2 levels in 6-OHDA-lesioned mice. |
| References |
|
| Additional Infomation |
Erucin is an isothiocyanate.
Erucin has been reported in Thulinella chrysantha, Brassica oleracea, and Brassica napus with data available. |
| Molecular Formula |
C6H11NS2
|
|---|---|
| Molecular Weight |
161.28
|
| Exact Mass |
161.033
|
| CAS # |
4430-36-8
|
| PubChem CID |
78160
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
250.6±23.0 °C at 760 mmHg
|
| Melting Point |
52 °C
|
| Flash Point |
105.4±22.6 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.531
|
| LogP |
2.39
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
9
|
| Complexity |
97.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CSCCCCN=C=S
|
| InChi Key |
IHQDGXUYTSZGOG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H11NS2/c1-9-5-3-2-4-7-6-8/h2-5H2,1H3
|
| Chemical Name |
1-isothiocyanato-4-methylsulfanylbutane
|
| Synonyms |
CCRIS9056 CCRIS-9056 CCRIS 9056
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~620.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2004 mL | 31.0020 mL | 62.0040 mL | |
| 5 mM | 1.2401 mL | 6.2004 mL | 12.4008 mL | |
| 10 mM | 0.6200 mL | 3.1002 mL | 6.2004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
